Advertisement
Advertisement
Sidapvia

Sidapvia

Manufacturer:

AstraZeneca

Distributor:

Zuellig Pharma
Concise Prescribing Info
Contents
Dapagliflozin propanediol monohydrate 10 mg, sitagliptin phosphate monohydrate 100 mg
Indications/Uses
Adjunct to diet & exercise to improve glycaemic control in adults w/ type 2 DM.
Dosage/Direction for Use
Adult 1 tab once daily taken at any time of the day.
Administration
May be taken with or without food: Swallow whole.
Contraindications
Special Precautions
Serious hypersensitivity reactions including anaphylaxis, angioedema & exfoliative skin conditions (eg, SJS); discontinue use if hypersensitivity reaction is suspected. Not for patients w/ type 1 DM. Not to be used for the treatment of diabetic ketoacidosis; discontinue or consider temporary interruption if ketoacidosis is suspected. Patients w/ predisposing factors to ketoacidosis including low β-cell function reserve resulting from pancreatic disorders (eg, type 1 diabetes, history of pancreatitis or pancreatic surgery), reduced insulin dose, caloric intake or increased insulin requirements due to infections, illness or surgery & alcohol abuse. Combination w/ medications known to cause hypoglycaemia eg, insulin & insulin secretagogues (eg, sulfonylureas). Discontinue use if pancreatitis is suspected. Patients w/ history of pancreatitis. Arthralgia; individually assess drug therapy continuation if patient presents w/ severe joint pain. Discontinue use if a patient develops blisters or erosions during therapy & bullous pemphigoid is suspected & consider referral to a dermatologist. Patients whom a dapagliflozin-induced BP drop could pose a risk (eg, patients w/ known CV disease, on an anti-hypertensive therapy w/ a history of hypotension or elderly patients). Monitor vol status (eg, physical exam, BP measurements, lab tests including haematocrit) & electrolytes in patients w/ intercurrent conditions may lead to vol depletion; consider temporary interruption for patients who develop vol depletion. Patients experiencing a symptom combination of pain, tenderness, erythema, or swelling in the genital or perineal area, w/ fever or malaise; discontinue use if Fournier's gangrene is suspected & institute prompt treatment. May affect the ability to drive or operate machines. Not to be used on patients w/ renal impairment (eGFR <45 mL/min/1.73 m2); evaluate renal function prior to treatment initiation & periodically thereafter. Not to be used in patients w/ severe hepatic impairment. Not to be used during pregnancy & lactation. Paed & adolescents. Elderly.
Adverse Reactions
Genital infection, UTI, URTI, nasopharyngitis; hypoglycaemia; headache; back pain; pollakuria, polyuria.
Drug Interactions
Dapagliflozin: Concomitant use w/ lithium may lead to a reduction in serum lithium conc. Possible increased risk of dehydration & hypotension w/ thiazide & loop diuretics. Not recommended to use 1,5-AG assay for monitoring glycaemic control.
MIMS Class
Antidiabetic Agents
ATC Classification
A10BD29 - sitagliptin and dapagliflozin ; Belongs to the class of combinations of oral blood glucose lowering drugs. Used in the treatment of diabetes.
A10BK01 - dapagliflozin ; Belongs to the class of sodium-glucose co-transporter 2 (SGLT2) inhibitors. Used in the treatment of diabetes.
A10BH01 - sitagliptin ; Belongs to the class of dipeptidyl peptidase 4 (DPP-4) inhibitors. Used in the treatment of diabetes.
Presentation/Packing
Form
Sidapvia 10/100 mg FC tab
Packing/Price
1's
Advertisement
Advertisement
Advertisement
Advertisement
Advertisement
Advertisement
Advertisement